Medication Guide App

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Get news by email or subscribe to our news feeds.

Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen

Posted today in Clinical Trials

WHITEHOUSE STATION, N.J. – August 26, 2014 -- Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical...

Read more...

Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII

Posted 5 days ago in Clinical Trials

DEERFIELD, Ill., August 21, 2014 - Baxter International Inc. (NYSE:BAX) today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to...

Read more...

Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies

Posted 6 days ago in Clinical Trials

INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. "These data are important for people suffering from...

Read more...

Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid

Posted 6 days ago in Clinical Trials

SILVER SPRING, Md., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as...

Read more...

Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Fragile X Syndrome

Posted 7 days ago in Clinical Trials

TEL AVIV, Israel, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that the first patient has been enrolled in a Phase IIb Fragile X study of MDX. The FDA...

Read more...

Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for ABSSSI

Posted 7 days ago in Clinical Trials

BEVERLY, MA–(Marketwired –August 19,2014)- Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in its Phase 2b trial comparing Brilacidin™ to daptomycin (Cubicin®) in patients with acute bacterial skin and skin structure infections...

Read more...

Auspex Pharmaceuticals Completes Enrollment in Phase 3 Registration Clinical Trial of SD-809

Posted 8 days ago in Clinical Trials

LA JOLLA, Calif., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that it has completed the enrollment of the planned 90 patients in its Phase 3 registration clinical trial (First-HD) of SD-809 for the potential treatment of...

Read more...

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection)

Posted 9 days ago in Clinical Trials

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of...

Read more...

Pfizer Announces FDA Acceptance Of And Priority Review Designation For BLA For Investigational Meningococcal B Vaccine

Posted 12 days ago in Clinical Trials

Thursday, August 14, 2014 - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority...

Read more...

Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis

Posted 2 weeks ago in Clinical Trials

August 11, 2014 -- Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that the Company has just received the final toxicology report for Brilacidin-OM. Cellceutix is developing Brilacidin-OM as a new treatment for oral mucositis, a common and often...

Read more...

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

Posted 2 weeks ago in Clinical Trials

SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia...

Read more...

FDA Modifies Tekmira's TKM-Ebola Clinical Hold to Partial Hold

Posted 2 weeks ago in Clinical Trials

VANCOUVER, British Columbia, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This action...

Read more...

Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology

Posted 2 weeks ago in Clinical Trials

LOS ANGELES--(BUSINESS WIRE)--Aug. 7, 2014-- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its oral presentation given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center, titled “Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue...

Read more...

NuvOx Pharma Begins Clinical Trial to Treat Brain Cancer

Posted 2 weeks ago in Clinical Trials

Tucson, AZ (PRWEB) August 07, 2014 - NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer. Glioblastoma multiforme (GBM), according to the Central...

Read more...

Idera Pharmaceuticals and The Myositis Association Advance the Clinical Development of IMO-8400 for Myositis

Posted 2 weeks ago in Clinical Trials

CAMBRIDGE, Mass. & ALEXANDRIA, Va.--(BUSINESS WIRE)--Aug. 7, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a...

Read more...

Integra LifeSciences Announces Completion of Its Multicenter Clinical Trial for the Treatment of Diabetic Foot Ulcers

Posted 3 weeks ago in Clinical Trials

PLAINSBORO, N.J., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed Its multicenter clinical trial evaluating the safety and effectiveness of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers ("the DFU study"). Integra Dermal Regeneration Template is an advanced bilayer skin replacement system designed to...

Read more...

Ignyta and Nerviano Announce License Agreement for Two First-in-Class Kinase Inhibitors

Posted 3 weeks ago in Clinical Trials

SAN DIEGO & NERVIANO, Italy--(BUSINESS WIRE) August 4, 2014 -- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a license agreement that grants Ignyta exclusive global development and commercialization rights to two new drug development programs, which Ignyta will...

Read more...

Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies

Posted 4 weeks ago in Clinical Trials

WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 30, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech’s PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell...

Read more...

Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid

Posted 4 weeks ago in Clinical Trials

Cambridge, MA and Herzliya Pituach, Israel – July 30, 2014 – Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: “IMNP.”; “Immune” or “the Company”) announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This...

Read more...

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab

Posted 4 weeks ago in Clinical Trials

Paris and Tarrytown, New York - July 30, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active...

Read more...
Older articles
Hide
(web1)